ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

Mitomycin
Colorectal and other GI cancers
Pancreatic, thyroid, and other endocrine cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

Mitomycin Rx

Generic Name and Formulations:
Mitomycin 5mg/vial, 20mg/vial, 40mg/vial; pwd for IV infusion after reconstitution and dilution; contains mannitol.

Company:
Various generic manufacturers

Therapeutic Use:

Indications for Mitomycin:

Disseminated adenocarcinoma of the stomach.

Adult:

Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments.

Children:

Not recommended.

Contraindications:

Thrombocytopenia. Coagulation disorders. Bleeding tendencies.

Warnings/Precautions:

Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with vinca alkaloids, other chemotherapy.

Pharmacological Class:

Cytotoxic antibiotic.

Adverse Reactions:

Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting.

Note:

Formerly known under the brand names Mitozytrex, Mutamycin.

How Supplied:

Contact supplier.

Indications for Mitomycin:

Disseminated adenocarcinoma of the pancreas.

Adult:

Give by IV infusion. 20mg/m2 as a single dose every 6–8 weeks. Discontinue if disease progresses after two courses. Myelosuppression: see literature for dose adjustments.

Children:

Not recommended.

Contraindications:

Thrombocytopenia. Coagulation disorders. Bleeding tendencies.

Warnings/Precautions:

Renal toxicity; serum creatinine >1.7mg: not recommended. Monitor platelets, WBCs, differential, hemoglobin repeatedly during and for at least 8 weeks after therapy. Avoid extravasation. Monitor fluid balance and avoid overhydration. Pregnancy, nursing mothers: not recommended.

Interactions:

Caution with vinca alkaloids, other chemotherapy.

Pharmacological Class:

Cytotoxic antibiotic.

Adverse Reactions:

Thrombocytopenia, leukopenia (cumulative myelosuppression); inj site reactions (eg, cellulitis), stomatitis, alopecia, renal toxicity, pulmonary toxicity (eg, pulmonary infiltrates); discontinue if occurs; hemolytic uremic syndrome, CHF, fever, anorexia, nausea, vomiting.

Note:

Formerly known under the brand names Mitozytrex, Mutamycin.

How Supplied:

Contact supplier.

Sign Up for Free e-newsletters